The company has several juicy growth opportunities ahead of it, a market professional tracking its fortunes believes.

Vertex has the revenue power to excel during any market environment.

Financial giants have made a conspicuous bullish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals (NASDAQ:VRTX) revealed 35 unusual trades. Delving into the ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening.

Vertex Pharmaceuticals' shares dropped due to poor first-quarter results. The company tends to run up after significant price drops. Vertex's business and prospects remain attractive. However, ...

Vertex Pharmaceuticals Incorporated faces slowing Trikafta/Kaftrio sales and a stock-price divergence with peers. Click for this VRTX earnings update.

Vertex Pharmaceuticals’ stock has lagged behind the broader market over the past year, but analysts remain moderately bullish about its prospects.

Learn more about whether Hut 8 Corp. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Investing.com - Vertex (NASDAQ: VRTX) reported fourth quarter EPS of $5.03, $0.05 worse than the analyst estimate of $5.08. Revenue for the quarter came in at $3.19B versus the consensus estimate of ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. VERX offers steady low-teens growth, expanding margins, and a sticky tax compliance software ...